1. Home
  2. CYTK vs MTH Comparison

CYTK vs MTH Comparison

Compare CYTK & MTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • MTH
  • Stock Information
  • Founded
  • CYTK 1997
  • MTH 1985
  • Country
  • CYTK United States
  • MTH United States
  • Employees
  • CYTK N/A
  • MTH N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • MTH Homebuilding
  • Sector
  • CYTK Health Care
  • MTH Consumer Discretionary
  • Exchange
  • CYTK Nasdaq
  • MTH Nasdaq
  • Market Cap
  • CYTK 5.6B
  • MTH 5.5B
  • IPO Year
  • CYTK 2004
  • MTH 1988
  • Fundamental
  • Price
  • CYTK $44.53
  • MTH $73.46
  • Analyst Decision
  • CYTK Strong Buy
  • MTH Buy
  • Analyst Count
  • CYTK 17
  • MTH 9
  • Target Price
  • CYTK $82.00
  • MTH $72.50
  • AVG Volume (30 Days)
  • CYTK 1.6M
  • MTH 1.1M
  • Earning Date
  • CYTK 05-07-2025
  • MTH 04-23-2025
  • Dividend Yield
  • CYTK N/A
  • MTH 2.65%
  • EPS Growth
  • CYTK N/A
  • MTH 7.63
  • EPS
  • CYTK N/A
  • MTH 10.72
  • Revenue
  • CYTK $18,474,000.00
  • MTH $6,395,035,000.00
  • Revenue This Year
  • CYTK $176.28
  • MTH $6.74
  • Revenue Next Year
  • CYTK $361.83
  • MTH $8.29
  • P/E Ratio
  • CYTK N/A
  • MTH $6.80
  • Revenue Growth
  • CYTK 145.34
  • MTH 4.18
  • 52 Week Low
  • CYTK $40.53
  • MTH $68.93
  • 52 Week High
  • CYTK $75.71
  • MTH $106.99
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 50.85
  • MTH 47.85
  • Support Level
  • CYTK $42.66
  • MTH $69.05
  • Resistance Level
  • CYTK $48.43
  • MTH $73.42
  • Average True Range (ATR)
  • CYTK 2.09
  • MTH 2.19
  • MACD
  • CYTK 0.28
  • MTH 0.18
  • Stochastic Oscillator
  • CYTK 51.02
  • MTH 33.34

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About MTH Meritage Homes Corporation

Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, which are comprised of ten states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Utah. The company operates with two principal business segments; homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes and providing warranty and customer services and the financial services segment offer title and escrow, mortgage, and insurance services. The company generates key revenue from the homebuilding segment.

Share on Social Networks: